Drugs / Gamunex
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00845650 | Feb 2009 → Oct 2010 | anthrax infection | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00417573 | Dec 2004 → Dec 2006 | infectious disease, selective IgG immunodeficiency | The Center for Rheumatic Disease, Allergy, & Immunology | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01281969 | Jan 2011 → Dec 2015 | autoimmune disease, obsessive-compulsive disorder | National Institute of Mental Health (NIMH) | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT02269163 Comparator | Jan 2016 → Jan 2019 | immunodeficiency disease | Prometic Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00376077 Comparator | Aug 2005 → Mar 2016 | autoimmune thrombocytopenic purpura | The Hospital for Sick Children | Completed | Missed primary |
Press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GAMUNEX | “Placebo followed by IVIG 1 g/kg (Gamunex® Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose” NCT00376077 ↗6“both given over 1 hour, followed in both cases by IVIG (Gamunex 10%) 1 g/kg over 2-3 hours” PMID 32282882 ↗ Apr 2020 “GAMUNEX® (immune globulin intravenous (human) 10% caprylate/chromatography purified).” NCT00845650 ↗ “Gammargard, Gammaplex, Gamunex, or Octogam IGIV Product” NCT02269163 ↗ |
| Known as | Intravenous Immunoglobulin | “Drug: Gamunex Intravenous Immunoglobulin” NCT01281969 ↗ |
| Modality | Protein / enzyme biologic | “IV immune globulin (IVIG)” PMID 32282882 ↗ Apr 2020 |
| Route | Intravenous | “IV immune globulin (IVIG)” PMID 32282882 ↗ Apr 2020 |